Vital

Dosing

Compounded Tirzepatide Dosage Chart: mg to Units by Vial

A compounded tirzepatide dosage chart in units: the label dose steps from 2.5 to 15 mg, converted to mL and U-100 syringe units at common compounded vial concentrations, with the math and the errors to avoid.

Last reviewed

The Vital angle

When you add a vial in Vital, you enter the mg in the vial and the liquid in mL, and the app shows the concentration, the U-100 units and mL to draw for the amount your prescriber gave you, and the doses per vial. It highlights a draw that is more than a 1 mL syringe holds, and each dose log keeps its unit, so old logs stay correct after a vial strength changes.

Compounded tirzepatide dosage chart in units: the short answer

A compounded tirzepatide dosage chart in units depends on one number: the concentration of your vial in mg per mL. Units on a U-100 insulin syringe measure volume, not drug. To convert, divide the mg amount by the concentration to get mL, then multiply by 100 to get units. Math example: 2.5 mg from a 10 mg/mL vial is 0.25 mL, which is 25 units.

The mg steps come from the FDA-approved labels. For Zepbound, the label lists a start of 2.5 mg once weekly for 4 weeks, then 5 mg, with increases in 2.5 mg steps after at least 4 weeks on a dose, up to 15 mg. The grid below turns those label steps into units at common compounded concentrations. It is math, not a dose plan. Your prescriber sets your dose, and your pharmacist confirms the draw.

The label dose steps

Brand tirzepatide is sold as Zepbound for weight reduction and sleep apnea, and as Mounjaro for type 2 diabetes. Compounded tirzepatide is not FDA-approved and has no label of its own. The steps below come from the Zepbound label, which lists:

Step Weekly amount the label lists Label notes
Start 2.5 mg For 4 weeks. The label says it is for starting only, not maintenance
Next 5 mg After 4 weeks at 2.5 mg
Further 7.5, 10, 12.5 mg Increase in 2.5 mg steps after at least 4 weeks on the current dose
Maximum 15 mg The highest weekly dose on the label

The label lists 5, 10, or 15 mg as maintenance doses for weight reduction, and 10 or 15 mg for sleep apnea. Your prescriber can keep you at a step for longer. A chart is not a reason to move up.

mg to units grid at common concentrations

Compounded vials come in many strengths. The concentrations below are examples that people often see on labels. Use the row for your exact label, and if your concentration is not here, use the formula. Every number is math, not a dose. Confirm every draw with your prescriber or pharmacist.

Amount 5 mg/mL 8 mg/mL 10 mg/mL 15 mg/mL 20 mg/mL
2.5 mg 50 units (0.50 mL) 31.25 units (0.3125 mL) 25 units (0.25 mL) 16.7 units (0.167 mL) 12.5 units (0.125 mL)
5 mg 100 units (1.00 mL) 62.5 units (0.625 mL) 50 units (0.50 mL) 33.3 units (0.333 mL) 25 units (0.25 mL)
7.5 mg 150 units* 93.75 units (0.9375 mL) 75 units (0.75 mL) 50 units (0.50 mL) 37.5 units (0.375 mL)
10 mg 200 units* 125 units* 100 units (1.00 mL) 66.7 units (0.667 mL) 50 units (0.50 mL)
12.5 mg 250 units* 156.25 units* 125 units* 83.3 units (0.833 mL) 62.5 units (0.625 mL)
15 mg 300 units* 187.5 units* 150 units* 100 units (1.00 mL) 75 units (0.75 mL)

*More than a 1 mL U-100 syringe holds. Do not split a draw into two syringes without instructions from your pharmacist. Ask if a different concentration fits your dose.

Some cells, such as 31.25 units or 16.7 units, fall between syringe lines. A number that you cannot read on your barrel is a reason to call your pharmacist, not to round on your own.

How to read the grid without errors

  1. Find the concentration on the label. It is written as mg/mL, such as "10 mg/mL." The total mg in the vial, such as "40 mg/4 mL," is a different number. Divide the total mg by the total mL to get the concentration.
  2. Find the amount your prescriber gave you, in mg. If your instruction is only in units, ask for the mg and the concentration as well.
  3. Read across to your concentration. The cell gives units and mL.
  4. Check the syringe scale. The grid uses U-100 syringes, where 1 unit is 0.01 mL. A U-40 syringe uses a different scale. See U-40 vs U-100 syringes.
  5. Write it down three ways. For example: "2.5 mg = 0.25 mL = 25 units on a U-100 syringe."

The free peptide calculator does the same math for any concentration. For help with the lines on the barrel, see how to read an insulin syringe.

Why the same dose can be 25 units or 50 units

The most common error is to carry a unit number from one vial to the next. Math example: 2.5 mg is 25 units at 10 mg/mL, but 50 units at 5 mg/mL. If a refill comes at a different strength and you keep the old unit number, you get half or double the intended amount.

The FDA has reported this kind of error with compounded semaglutide. Some patients took 5 to 20 times the intended dose. In one case, a patient told to draw 5 units drew 50 units. By May 31, 2026, the FDA had more than 730 adverse event reports with compounded tirzepatide. The FDA also received reports with compounded semaglutide or tirzepatide given at doses above the FDA-approved label.

Other common errors:

  • Reading mg as units. "2.5" on a prescription is mg. It is not 2.5 units.
  • A label with total mg only. "20 mg vial" does not tell you the concentration until you know the volume.
  • A syringe that is too large. Small volumes are hard to read on a 1 mL barrel. The FDA asks compounders to give a syringe sized for the intended dose.

Compounded tirzepatide and its legal status

Compounded tirzepatide is not FDA-approved. The FDA has not reviewed compounded versions for safety, quality, or effect. The FDA declared the tirzepatide shortage resolved on December 19, 2024. The grace period for state-licensed pharmacies ended in March 2025, and for outsourcing facilities on March 19, 2025.

In an April 1, 2026 update, the FDA said tirzepatide is not on its drug shortage list or on the 503B bulks list. If you get compounded tirzepatide, get it with a prescription from a state-licensed pharmacy, and do not buy products labeled "for research use only." The FDA also says to throw away a compounded multi-dose vial 28 days after the first use, even if the compounder says that you can use it longer. For storage rules, see compounded GLP-1 vial storage. For how many doses a vial gives, see how many doses in a vial.

How Vital tracks a tirzepatide vial

A vial dose has more parts than a pen dose: the mg, the concentration, the volume, and the syringe. Vital keeps them together.

When you add a vial in Vital, you enter the mg in the vial and the liquid in mL. The app shows the concentration, the U-100 units and mL to draw for the amount your prescriber gave you, and the doses per vial. It highlights a draw that is more than a 1 mL syringe holds. Each dose log keeps the unit you used, so a log from your 10 mg/mL vial stays correct after you switch to a 20 mg/mL vial.

You can set a weekly reminder, log the injection site, and make a PDF report of your doses for your prescriber. For a logged dose, the "Still in your system" card shows an estimate, based on half-life, of the percent of that dose that is left. Vital does not suggest a dose. To see the half-life idea without the app, try the free GLP-1 level chart.

Warning signs that need care now

Get urgent care if you have:

  • Severe stomach pain that does not go away, with or without vomiting, which can be a sign of pancreatitis or a gallbladder problem.
  • Vomiting or diarrhea that stops you from keeping fluids down, or very little urine.
  • Swelling of the face, lips, or throat, a bad rash, or trouble breathing.
  • Shakiness, sweating, or confusion, mainly if you also take insulin or a sulfonylurea.

If you think you drew too much, call your prescriber or Poison Help at 1-800-222-1222. For a new dose step, see side effects after a dose increase. For a switch between drugs, see switching semaglutide to tirzepatide.


Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. Vital is independent and not affiliated with these companies.

Free toolPeptide reconstitution calculator

Things to watch

Practical flags drawn from prescribing information and clinical guidance. Vital surfaces these in the dose log to help you spot them early.

  • Unit numbers carried to a new vial

    The same mg amount is 25 units at 10 mg/mL and 50 units at 5 mg/mL. A refill at a different strength makes an old unit number wrong.

  • mg read as units

    A prescription for 2.5 mg is not 2.5 units. The FDA reported dosing errors with compounded semaglutide vials from confusion between mg, mL, and units.

  • Labels with total mg only

    A "20 mg vial" gives no concentration until you know the volume. Divide total mg by total mL to get mg per mL.

  • Draws over 1 mL

    At low concentrations, higher steps need more than a 1 mL U-100 syringe holds. Ask the pharmacist before you split a draw.

  • Products labeled for research use

    The FDA has warned sellers of tirzepatide labeled "for research purposes" or "not for human consumption." These are not made for patients.

Frequently asked questions

  • It depends on the concentration. As math: at 10 mg/mL, 2.5 mg is 0.25 mL, or 25 units on a U-100 syringe. At 5 mg/mL it is 50 units, and at 20 mg/mL it is 12.5 units. Confirm the draw with your pharmacist.

  • Divide the mg amount by the concentration in mg per mL to get mL. Multiply the mL by 100 to get units on a U-100 syringe. Confirm the result with your prescriber or pharmacist.

  • As math: 5 mg ÷ 10 mg/mL = 0.5 mL, which is 50 units on a U-100 syringe. This is a math example, not a dose.

  • The Zepbound label lists 2.5 mg once weekly for 4 weeks to start, then 5 mg, with increases in 2.5 mg steps after at least 4 weeks on a dose, up to 15 mg weekly. Your prescriber decides if and when you change.

  • No. The FDA does not review compounded drugs for safety, quality, or effect. The FDA declared the tirzepatide shortage resolved in December 2024.

  • A 1 mL U-100 syringe holds 100 units. Do not split a draw on your own. Ask your pharmacist about the right syringe or a different concentration.

Sources

  1. Zepbound (tirzepatide) Prescribing Information · Eli Lilly and Company
  2. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss · U.S. Food and Drug Administration
  3. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize · U.S. Food and Drug Administration
  4. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products · U.S. Food and Drug Administration
  5. Injection Safety: Clinical Safety Practices · Centers for Disease Control and Prevention

This page summarizes publicly available information from the sources listed above and is for educational use only. It is not medical advice. Consult a qualified healthcare professional for personal dosing guidance.

Track every shot, every change

Vital logs every GLP-1 injection and peptide dose, then surfaces patterns your scale can't show. Free on iOS and Android.